数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Alzheimer’s disease (AD) currently burdens over 55 million people on a worldwide scale and is predicted to triple by 2050 [1].
方法
Eligible GLP-1RA agents included: lixisenatide, liraglutide, semaglutide, albiglutide, dulaglutide, exenatide in the search.；We included studies evaluating the use of GLP-1RA(s) independently of nutritional status, on cognitive performance evaluation tests following treatment.；Studies providing raw mean and standard deviation of cognitive tests for the outcome of interest were also included in the meta-analysis.；Exclusion criteria included: (i) non-original research (including reviews, comments, editorials, perspectives), (ii) non-English language because the review team did not have sufficient linguistic resources to reliably assess eligibility, methods and data extraction, (iii) retracted publications, (iv) animal or in vitro studies, (v) conference abstracts, (vi) lack of specific information for performing a meta-analysis.
核心结论
The pooled random-effects estimate showed no evidence of a treatment effect (Hedges’ g = 0.014, 95% CI: −0.061 to 0.088; p = 0.515), with tau2 = 0 and I2 = 0%.；In the sensitivity analysis excluding the dominant Cukierman trial [24] from global cognition, the remaining two studies yielded g = −0.205 (95% CI: −2.678 to 2.269; p = 0.484), with tau2 = 0 and I2 = 0%. ‖ 结论：Larger randomized controlled trials specifically designed to assess cognition, with standardized and prespecified cognitive outcomes and adequate follow-up, are required to determine whether GLP-1RA(s) hold potential in adults at risk of developing AD.
局限
Given heterogeneity in study populations, pharmacological formulations, dosing regimens, and intervention periods, current evidence remains insufficient to draw substantiated conclusions about the efficacy of GLP-1RA(s) in patients with MCI.；With only two or three studies in pooled analyses, estimates of between-study heterogeneity are imprecise; therefore, tau2 and I2 should be interpreted cautiously.；An additional limitation is that no single cognitive domain, instrument, or assessment time point was prespecified as the primary cognitive outcome in the registered protocol.
对本项目的价值
★★★★☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。最大样本量约 13,711；设计 RCT、Meta 分析。
全文来源
PMC JATS 全文（正文 32,013 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- 期刊与标识：Nutrients · PMID 42942883 · DOI 10.3390/nu18203312**
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。